Tech Company Financing Transactions
Recombinetics Funding Round
On 1/23/2013, Recombinetics landed $250 thousand in Series A investment from private investors.
Transaction Overview
Company Name
Announced On
1/23/2013
Transaction Type
Venture Equity
Amount
$250,000
Round
Series A
Investors
Proceeds Purpose
Recombinetics hopes to ramp up production to 600 diseased pigs per year by 2016.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1246 University Ave. W
Saint Paul, MN 55104
USA
Saint Paul, MN 55104
USA
Phone
Website
Email Address
Not Recorded
Overview
At Recombinetics, we use unique precision genetics technologies to provide scientists who study persistent health risks -- obesity, diabetes, cancer, and high heart disease --with the research tools they need to understand and combat disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tammy Lee
Chief Financial Officer
David Aberle
Chief Scientific Officer
Mitch Abrahamsen
Chief Scientific Officer
Tad Sonstegard
VP - Bus. Development
Justin Zenanko
VP - General Counsel
John Burtis
VP - R & D
Daniel Carlson
Browse more venture capital transactions:
Prev: 1/23/2013: Cylene Pharmaceuticals venture capital transaction
Next: 1/23/2013: NetBase venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs